Tirzepatide vs Dulaglutide
Head-to-head comparison of Tirzepatide and Dulaglutide for research applications. Both peptides are studied for Metabolic Health, but they differ significantly in mechanism and evidence level.
Side-by-Side Comparison
| Attribute | Tirzepatide | Dulaglutide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / GLP-1 Agonist |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | Dulaglutide is a GLP-1 receptor agonist consisting of two identical disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence (90% homology to native GLP-1) fused to a modified human IgG4 Fc fragment via a small peptide linker. |
| Evidence Rating | A — FDA Approved | A — FDA Approved |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | FDA-approved (Trulicity for T2D, September 2014; cardiovascular risk reduction, 2020) |
| Safety Profile | Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems; FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath | Common (>=5%): nausea (12-21%), diarrhea (8-13%), vomiting (6-12%), abdominal pain, decreased appetite; GI side effects are dose-dependent and typically transient, decreasing after the first 2-4 weeks |
| Molecular Weight | ~4813.5 g/mol | ~59,670 g/mol (fusion protein) |
| Half-Life | ~5 days (116 hours) | ~5 days (approximately 120 hours) |
Overview
Tirzepatide and Dulaglutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
Dulaglutide — Mechanism & Evidence
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. It is a fusion protein consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a small peptide linker (MW ~59,670 g/mol). The Fc fusion extends its half-life to approximately 5 days, enabling once-weekly dosing. Dulaglutide is administered via a single-dose pen device that does not require reconstitution.
Key claims: Effective glycemic control in type 2 diabetes; Produces clinically meaningful weight loss; Reduces major adverse cardiovascular events.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
Tirzepatide is also researched for: Weight Management.
Dulaglutide is also researched for: Cardiovascular.
Safety Considerations
Tirzepatide: Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath Immunogenicity: 51% developed antibodies with no observed effect on efficacy
Dulaglutide: Common (>=5%): nausea (12-21%), diarrhea (8-13%), vomiting (6-12%), abdominal pain, decreased appetite GI side effects are dose-dependent and typically transient, decreasing after the first 2-4 weeks Hypoglycemia risk increased when combined with insulin or sulfonylureas
Shop Research Peptides
Tirzepatide 10mg
10mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Tirzepatide Tied to Reduced Heart Attack Risk in High-Risk Patients
A recent report highlights that the GLP-1 drug tirzepatide is associated with a lower risk of heart attacks in patients considered high-risk. The finding adds to growing evidence of cardiovascular benefits for this class of medications. Details from the WDBJ7 report are summarized here.
Tirzepatide News: GLP-1 Drug Demand Surges, MACE Risk May Drop
Recent reports suggest tirzepatide, a GLP-1 drug, may reduce MACE risk in high-risk patients while demand for injectable GLP-1 therapies remains strong. This analysis covers the latest tirzepatide news and its implications for peptide research and clinical practice.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe